Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Rainbow BioSciences, a biotech subsidiary of Rainbow Coral (RBCC), and Amarantus Biosciences have moved into the final stages of the terms to jointly move the Amarantus NuroPro Parkinson's diagnostic platform towards commercialization.
Subscribe to our email newsletter
RBCC CEO Patrick Brown said NuroPro has the potential to diagnose Parkinson’s disease early allowing physicians to initiate treatment regimens earlier, as well as conduct research of clinical-stage disease-modifying treatments on earlier-stage patients.
The deal is being streamlined to enable completion of the final stages of the NuroPro program to commercially introduce the product in the market.
The NuroPro test identifies differentiated levels of proteins and peptides in the blood of patients who have Parkinson’s disease with those who do not and it is expected that phase 2 clinical studies for the test will begin in 2013.
Amarantus president and CEO Gerald Commissiong said the transaction will allow Amarantus to gain upside from the licensing of the NuroPro asset, while defraying the costs of the project to focus its internal resources on the MANF Program for Parkinson’s disease and Traumatic Brain Injury.
”As NuroPro advances towards commercialization, we expect it could become a key differentiating component of our clinical development program of MANF for Parkinson’s disease," Commissiong added.
RBCC expects a deal with Amarantus to capitalize on the growing market for Parkinson’s in the near-term while Amarantus expects RBCC help to further enable the development of the MANF.